Dr. Pan of St. Louis University has no relevant financial relationships to disclose.)
Dr. Thomas of Hackensack University Medical Center, Hackensack Meridian School of Medicine at Seton Hall University, received consulting fees from Pharnext and Acceleron.)
Dr. Weimer of Columbia University has received consulting fees from Roche.)
Treatment of neuropathic pain is an ongoing challenge for clinicians. In this article, the authors summarize pharmacological management based on published clinical trials. Not all medications mentioned in this article have been investigated in placebo-controlled, double-blind, randomized trials. The aim of this article is to provide a variety of updated information so clinicians can choose an optimal treatment for an individual patient.
• The treatment must be individualized.
• Combination of different agents should be considered in some patients.
• Slow dose escalation may improve drug tolerability.
Historical note and terminology
Neuropathic pain results from injury to the central or peripheral nerve systems and is characterized by a neuronal hyperexcitability. Treatment of painful neuropathies has been a challenge to clinicians. Definitive clinical trials to evaluate the efficacy of pharmacological agents or other therapies require careful randomization of subjects representative of the relevant population, appropriate sample sizes, and an adequate number of reliable measurement scales. One of the challenges stems from the fact that placebo treatments are effective in a significant number of patients (Petersen et al 2012). Treatment of central pain following stroke or spinal cord injury is similar to the treatment of painful neuropathy. This article will focus on painful neuropathy.
The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.
If you are a subscriber, please log in.
If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.